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At the wound’s edge
Tissue repair is a homeostatic response that involves a wide array 
of cellular and molecular events. Interestingly, wounding has-
tens skin carcinogenesis in mouse models. Type II keratins 6a 
and 6b are induced in epidermal keratinocytes after skin wound-
ing, although ablation of these genes in keratinocytes results in 
increased migration. Rotty and Coulombe recently examined 
the role of these structural proteins and the nonreceptor tyrosine 
kinase Src (which plays a role in cell migration) in wound healing. 
The increased migratory phenotype of K6-deficient cells resulted 
from activation of Src kinase and Src substrates that facilitate cell 
migration. K6 was found to bind to Src dynamically in the deter-
gent-resistant membranes, known sites of Src regulation. Thus, K6 
functions in the regulation and optimization of epithelial migra-
tion during wound healing via dampening of the activation of Src 
in wound-activated keratinocytes at the leading edge. (J Cell Biol 
197:381–9, 2012) Selected by S. Yuspa
MicroTuning
Distinct CD4+ T-cell subsets, including T helper type 17 (Th17) 
cells and natural and induced regulatory T cells (nTregs and 
iTregs), are thought to exhibit plasticity, and the roles of micro-
RNAs (miRNAs), which are involved in this T-cell plasticity deci-
sion via regulation of gene expression at the posttranscriptional 
level, remain an area of intense investigation. Recently, Takahashi 
and colleagues found that miR-10a, which is highly expressed in 
nTregs, is induced by retinoic acid (RA) and transforming growth 
factor-β and influences the plasticity of these cells. This miRNA 
directly targets expression of the transcriptional repressor Bcl-6 
and the corepressor Ncor2 and ultimately constrains conversion 
of iTregs to follicular Th cells. Furthermore, miR-10a inhibits Th17-
cell differentiation in a manner dependent on induction of the 
transcription factor T-bet by RA. This factor therefore contributes to 
maintenance of the Treg phenotype by targeting factors that favor 
plasticity. Moreover, regulation of miR-10a may be useful to fine-
tune factors that influence the stability-versus-plasticity decision in 
Th cells. (Nat Immunol 13:587–95, 2012) Selected by M. Amagai
Reconfiguration of memory
A recent randomized controlled trial demonstrated that 
rituximab, the chimeric mouse–human IgG1 monoclonal anti-
body that targets CD20 on B lymphocytes before differentiation, 
can provide long-term benefits to a subset of patients with anti-
myelin-associated glycoprotein (anti-MAG) neuropathy, an 
autoimmune disease of the peripheral nervous system mediated 
by MAG-specific IgM autoantibodies. Maurer and colleagues 
found that the long-term immunomodulatory effects and clinical 
disease remission following treatment with rituximab, which has 
received approval from the US Food and Drug Administration 
for a variety of autoimmune conditions, were mediated by the 
dramatic reduction of expanded autoreactive IgM memory B 
cells, highlighting a reconfiguration of B-cell memory. The pres-
ence of oligoclonal expansion in the IgM memory B-cell com-
partment before treatment, the ability of these immune cells to 
recognize MAG antigen, and the persistence of these cells in 
patients with stable or worsened disease after rituximab treat-
ment allowed nonresponders to be separated from clinical 
responders. Thus, MAG-specific IgM memory cells are impor-
tant for the pathogenesis of this autoimmune neuropathy. (J Clin 
Invest 122:1393–402, 2012) Selected by J. Stanley
New field guide
Analysis of squamous cell carcinomas led to the notion of field 
cancerization because frequent tumor multiplicity and changes 
to epithelial and mesenchymal changes are observed beyond the 
neoplastic area. Hu and colleagues demonstrated that loss of the 
CSL/RBP-Jκ gene that encodes the Notch signaling effector CSL 
in mice resulted in stromal atrophy and inflammation, which are 
potent triggers of epithelial tumors. These mice exhibited features 
reminiscent of field cancerization: multifocal tumors, expanded 
alterations of surrounding epithelium, and atrophic changes in 
the underlying stroma. Similar genetic and cellular changes were 
observed in human skin samples, indicating potential clinical 
significance. Importantly, treatment of the RBP-Jκ mutant mice 
with an immunosuppressant COX-2 inhibitor led to delayed for-
mation of focal lesions and tumors, suggesting that inhibition of 
inflammation may be used to prevent or retard secondary tumor 
development even in patients with field cancerization. (Cell 
149:1207–20, 2012). Selected by B. Gilchrest
Carcinoma intercept
Basal cell nevus syndrome is characterized by the presence of 
hundreds to thousands of basal cell carcinomas (BCCs). Patients 
with this syndrome harbor a defective copy of the Hedgehog 
inhibiting tumor-suppressor gene PTCH1, and essentially all 
their BCCs exhibit enhanced Hedgehog signaling. This year, the 
US Food and Drug Administration approved the use of the low-
molecular-weight Hedgehog signaling inhibitor vismodegib 
for treatment of locally advanced or metastatic BCCs. Pursuing 
a different indication, Tang and colleagues enrolled 41 
individuals with basal cell nevus syndrome in a randomized, 
double-blind, placebo-controlled trial of this drug. Vismodegib 
significantly reduced the appearance of new surgically eligible 
BCCs in these patients and also decreased the initially substan-
tial burden of these BCCs. Although the drug was effective, 
nearly 54% of the patients discontinued vismodegib because 
of mild or moderate adverse effects. The authors concluded that 
these results are consistent with the concept of cancer inter-
ception, which involves the blockade of further tumor growth 
before the lesions become clinically apparent. (N Engl J Med 
366:2180–8, 2012) Selected by B. Gilchrest
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